Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19048826 | LIPID COMPOSITION TARGETING ANTIGEN-PRESENTING CELLS AND USE THEREOF | February 2025 | September 2025 | Allow | 7 | 1 | 0 | No | No |
| 18758151 | METHODS AND COMPOSITIONS FOR TREATING AND PROTECTING AGAINST PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS | June 2024 | July 2025 | Allow | 13 | 2 | 0 | No | No |
| 18737778 | IMMUNOCOMPETENT CELL AND EXPRESSION VECTOR EXPRESSING REGULATORY FACTORS OF IMMUNE FUNCTION, AND CHIMERIC ANTIGEN RECEPTOR | June 2024 | December 2025 | Abandon | 18 | 2 | 1 | No | No |
| 18669712 | ENDONUCLEASE SYSTEMS | May 2024 | May 2025 | Allow | 11 | 1 | 1 | Yes | No |
| 18653454 | BASE EDITING ENZYMES | May 2024 | August 2025 | Allow | 15 | 1 | 1 | Yes | No |
| 18702749 | GENE EDITING METHODS FOR TREATING ALPHA-1 ANTITRYPSIN (AAT) DEFICIENCY | April 2024 | March 2026 | Allow | 23 | 1 | 0 | No | No |
| 18597673 | RIBOSWITCH MODULATED GENE THERAPY FOR RETINAL DISEASES | March 2024 | December 2024 | Allow | 10 | 1 | 0 | Yes | No |
| 18477788 | POLYRIBONUCLEOTIDES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF | September 2023 | September 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18474327 | Therapeutic Editing | September 2023 | February 2026 | Abandon | 29 | 0 | 1 | No | No |
| 18472824 | ENGINEERED RETRONS AND METHODS OF USE | September 2023 | March 2024 | Allow | 6 | 0 | 0 | Yes | No |
| 18457276 | ENGINEERED ADENOSINE DEAMINASES AND BASE EDITORS THEREOF | August 2023 | August 2024 | Allow | 12 | 1 | 1 | Yes | No |
| 18447536 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | August 2023 | February 2024 | Allow | 6 | 0 | 1 | Yes | No |
| 18447681 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | August 2023 | June 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18447515 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | August 2023 | February 2024 | Allow | 6 | 0 | 1 | Yes | No |
| 18362867 | Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent | July 2023 | March 2026 | Allow | 31 | 4 | 1 | Yes | No |
| 18356013 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | July 2023 | February 2024 | Allow | 7 | 0 | 1 | Yes | No |
| 18355380 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS | July 2023 | September 2025 | Allow | 26 | 2 | 0 | Yes | No |
| 18331092 | ENGINEERING CELL LINES CAPABLE OF PROLIFERATION IN GROWTH FACTOR FREE MEDIA FORMULATIONS | June 2023 | November 2025 | Allow | 30 | 4 | 1 | Yes | No |
| 18319042 | GENE EDITING-BASED METHOD OF ATTENUATING THE BETA-AMYLOID PATHWAY | May 2023 | August 2025 | Allow | 27 | 1 | 0 | No | No |
| 18127936 | IMMUNOENGINEERED PLURIPOTENT CELLS | March 2023 | September 2024 | Abandon | 18 | 0 | 0 | No | No |
| 18190063 | CRISPR SYSTEMS WITH ENGINEERED DUAL GUIDE NUCLEIC ACIDS | March 2023 | December 2024 | Allow | 21 | 2 | 1 | Yes | No |
| 18120007 | USE NOVEL LIGHT SENSITIVE CHANNEL PROTEIN VR 1.0 IN PREPARATION OF RETINAL PHOTORECEPTOR CELL DEGENERATIVE DISEASE DRUG | March 2023 | January 2024 | Allow | 10 | 1 | 0 | No | No |
| 18174397 | COMPOSITIONS, METHODS, MODULES AND INSTRUMENTS FOR AUTOMATED NUCLEIC ACID-GUIDED NUCLEASE EDITING IN MAMMALIAN CELLS USING MICROCARRIERS | February 2023 | September 2025 | Abandon | 31 | 2 | 0 | No | No |
| 18109759 | Process for extracellular secretion of Brazzein | February 2023 | December 2025 | Allow | 34 | 1 | 0 | No | No |
| 18161560 | ENGINEERED MEGANUCLEASES THAT TARGET HUMAN MITOCHONDRIAL GENOMES | January 2023 | August 2023 | Allow | 7 | 0 | 0 | Yes | No |
| 18101867 | ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS, ENZYMES AND GUIDE SCAFFOLDS OF CAS9 ORTHOLOGS AND VARIANTS FOR SEQUENCE MANIPULATION | January 2023 | September 2024 | Allow | 20 | 1 | 0 | No | No |
| 18087673 | ENGINEERED RETRONS AND METHODS OF USE | December 2022 | September 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 18049582 | ALTERNATIVE NUCLEIC ACID MOLECULES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF | October 2022 | June 2025 | Abandon | 32 | 0 | 1 | No | No |
| 17963889 | CRISPR SYSTEMS WITH ENGINEERED DUAL GUIDE NUCLEIC ACIDS | October 2022 | November 2025 | Abandon | 37 | 2 | 1 | No | No |
| 17931535 | Guide RNAs with Chemical Modification for Prime Editing | September 2022 | September 2023 | Allow | 12 | 2 | 0 | Yes | No |
| 17848330 | ENGINEERED TARGET SPECIFIC NUCLEASES | June 2022 | January 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17781877 | Therapeutic Editing | June 2022 | August 2023 | Allow | 14 | 1 | 0 | Yes | No |
| 17825665 | CODON OPTIMIZED RPGRORF15 GENES AND USES THEREOF | May 2022 | June 2023 | Abandon | 13 | 1 | 0 | No | No |
| 17751195 | Adeno-Associated Virus Vector Delivery of a Fragment of Micro-Dystrophin to Treat Muscular Dystrophy | May 2022 | October 2023 | Allow | 17 | 3 | 0 | Yes | No |
| 17748889 | Immunocompetent Cell and Expression Vector Expressing Regulatory Factors of Immune Function | May 2022 | November 2023 | Allow | 18 | 2 | 0 | Yes | No |
| 17738585 | NOVEL METHODS FOR EARLY IDENTIFICATION OF BONE HEALING ABILITY IN INJURED PATIENTS | May 2022 | February 2026 | Allow | 45 | 2 | 1 | Yes | No |
| 17710464 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS TARGETING TRIM7 | March 2022 | May 2024 | Allow | 26 | 1 | 1 | No | No |
| 17654300 | ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR RESTORING F8 GENE FUNCTION AND METHODS OF USE THEREOF | March 2022 | July 2023 | Allow | 16 | 1 | 0 | Yes | No |
| 17580228 | ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF B-SARCOGLYCAN AND MICRORNA-29 AND THE TREATMENT OF MUSCULAR DYSTROPHY | January 2022 | October 2023 | Allow | 21 | 2 | 0 | Yes | No |
| 17529936 | RECOMBINASE-RECOGNITION SITE PAIRS AND METHODS OF USE | November 2021 | July 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17525283 | METHOD FOR CONSTRUCTING TREHALOSE MULTI-ENZYME COMPLEX IN VITRO MEDIATED BY ARTIFICIAL SCAFFOLD PROTEIN | November 2021 | May 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17523821 | ELECTROPORATION MODULES AND INSTRUMENTATION | November 2021 | January 2023 | Allow | 15 | 1 | 0 | No | No |
| 17453702 | GENE THERAPY METHODS | November 2021 | August 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17506419 | METHODS AND COMPOSITIONS FOR DIRECTED GENOME EDITING | October 2021 | February 2025 | Abandon | 40 | 2 | 1 | No | No |
| 17506572 | CRISPR SYSTEMS WITH ENGINEERED DUAL GUIDE NUCLEIC ACIDS | October 2021 | October 2025 | Allow | 48 | 2 | 1 | No | No |
| 17494457 | Gene Editing-Based Method of Attenuating the Beta-Amyloid Pathway | October 2021 | February 2023 | Allow | 17 | 1 | 0 | Yes | No |
| 17490416 | HUMAN PAH EXPRESSION CASSETTE FOR TREATMENT OF PKU BY LIVER-DIRECTED GENE REPLACEMENT THERAPY | September 2021 | July 2024 | Allow | 34 | 1 | 1 | Yes | No |
| 17486735 | Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent | September 2021 | April 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17468086 | SYSTEMIC DELIVERY OF ADENO-ASSOCIATED VIRUS VECTOR EXPRESSING GAMMA-SARCOGLYCAN AND THE TREATMENT OF MUSCULAR DYSTROPHY | September 2021 | January 2024 | Allow | 28 | 2 | 1 | No | No |
| 17461716 | CODON OPTIMIZED RPGRORF15 GENES AND USES THEREOF | August 2021 | January 2022 | Allow | 5 | 0 | 0 | Yes | No |
| 17428401 | RECOMBINANT VECTORS SUITABLE FOR THE TREATMENT OF IPEX SYNDROME | August 2021 | November 2025 | Abandon | 51 | 2 | 0 | Yes | No |
| 17368216 | BUDDING YEAST WITH HUMAN CHROMATIN | July 2021 | June 2023 | Allow | 23 | 1 | 1 | Yes | No |
| 17365846 | SYNTHETIC DNA VECTORS AND METHODS OF USE | July 2021 | February 2023 | Allow | 20 | 2 | 1 | Yes | No |
| 17299024 | USE OF ACYL COENZYME A: CHOLESTEROL ACYLTRANSFERASE-1 IN DIAGNOSIS AND TREATMENT OF LIVER CANCER | June 2021 | October 2025 | Allow | 52 | 2 | 1 | No | No |
| 17335500 | Programmable Cleavage of Double-Stranded DNA | June 2021 | March 2026 | Abandon | 57 | 3 | 1 | No | Yes |
| 17244574 | GENE THERAPY VECTOR FOR TREATING RETINITIS PIGMENTOSA DISEASE | April 2021 | August 2023 | Allow | 27 | 1 | 0 | Yes | No |
| 17289015 | USE OF NW_006883358.1 IN CHO CELL GENOME FOR STABLE EXPRESSION OF PROTEIN | April 2021 | March 2026 | Abandon | 58 | 2 | 0 | No | No |
| 17239540 | COMPOSITIONS, METHODS, MODULES AND INSTRUMENTS FOR AUTOMATED NUCLEIC ACID-GUIDED NUCLEASE EDITING IN MAMMALIAN CELLS USING MICROCARRIERS | April 2021 | October 2022 | Allow | 18 | 3 | 1 | Yes | No |
| 17236556 | GENETIC DATA COMPRESSION AND METHODS OF USE | April 2021 | March 2025 | Allow | 47 | 3 | 1 | Yes | No |
| 17230484 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS | April 2021 | April 2023 | Allow | 24 | 1 | 0 | No | No |
| 17279271 | METHOD FOR PROMOTING N-ACETYLGLUCOSAMINE SYNTHESIS BY USING GLCN6P RESPONSIVE ELEMENT | March 2021 | December 2024 | Allow | 45 | 1 | 0 | No | No |
| 17206522 | METHODS AND COMPOSITIONS FOR DIRECTED GENOME EDITING | March 2021 | October 2021 | Allow | 7 | 2 | 1 | Yes | No |
| 17273805 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEART DISEASE | March 2021 | February 2026 | Abandon | 60 | 2 | 1 | Yes | No |
| 17180741 | GENETIC TOOLBOX FOR METABOLIC ENGINEERING OF NON-CONVENTIONAL YEAST | February 2021 | June 2024 | Allow | 39 | 2 | 0 | Yes | No |
| 17178737 | COMPOSITIONS AND METHODS FOR GENOMIC EDITING BY INSERTION OF DONOR POLYNUCLEOTIDES | February 2021 | January 2022 | Allow | 11 | 2 | 1 | Yes | No |
| 17173137 | INCREASED NUCLEIC-ACID GUIDED CELL EDITING IN YEAST | February 2021 | October 2023 | Abandon | 33 | 0 | 1 | No | No |
| 17158488 | ELECTROPORATION MODULES AND INSTRUMENTATION | January 2021 | November 2021 | Allow | 9 | 2 | 1 | Yes | No |
| 17132694 | IDENTIFICATION OF SPATIAL BIOMARKERS OF HEART DISORDERS AND METHODS OF USING THE SAME | December 2020 | September 2024 | Abandon | 45 | 2 | 1 | Yes | No |
| 16973894 | MATERIALS AND METHODS FOR MODULATING INTRAOCULAR AND INTRACRANIAL PRESSURE | December 2020 | January 2026 | Abandon | 60 | 2 | 1 | No | No |
| 17101299 | COMPOUNDS AND METHODS FOR MODULATING ANGIOTENSINOGEN EXPRESSION | November 2020 | October 2025 | Allow | 59 | 1 | 1 | Yes | No |
| 17039575 | Cell-Free Expression System Having Novel Inorganic Polyphosphate-Based Energy Regeneration | September 2020 | November 2024 | Allow | 50 | 3 | 1 | No | No |
| 17032657 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | September 2020 | September 2024 | Abandon | 48 | 1 | 1 | No | No |
| 17040058 | CRISPR ASSOCIATED PROTEIN REACTIVE T CELL IMMUNITY | September 2020 | July 2025 | Abandon | 58 | 2 | 1 | No | No |
| 16966682 | DRUG FOR CHRONIC INFLAMMATORY DISEASE AND METHOD FOR EVALUATING SUSCEPTIBILITY TO CHRONIC INFLAMMATORY DISEASE | July 2020 | March 2024 | Abandon | 44 | 1 | 1 | No | No |
| 16934970 | SYNTHETIC GENETIC ELEMENTS FOR BIOMANUFACTURE | July 2020 | January 2024 | Allow | 42 | 1 | 1 | No | No |
| 16933780 | CAPSID-MODIFIED RAAV VECTORS AND METHODS OF USE | July 2020 | April 2025 | Abandon | 57 | 2 | 0 | No | No |
| 16920051 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | July 2020 | January 2024 | Abandon | 43 | 1 | 0 | No | No |
| 16769522 | ENGINEERED UBIQUITOUS CHROMATIN OPENING ELEMENTS AND USES THEREOF | June 2020 | October 2023 | Abandon | 40 | 1 | 0 | No | No |
| 16881871 | MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS | May 2020 | October 2023 | Allow | 41 | 2 | 0 | Yes | No |
| 16871736 | EXPRESSION CONSTRUCTS, HOST CELLS, AND METHODS FOR PRODUCING INSULIN | May 2020 | April 2025 | Abandon | 59 | 3 | 1 | No | No |
| 16756756 | METHODS AND COMPOSITIONS FOR TREATING AND PROTECTING AGAINST PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS | April 2020 | March 2024 | Allow | 47 | 1 | 2 | Yes | No |
| 16846325 | Compositions and Methods for Inducing an Enhanced Immune Response Using Poxvirus Vectors | April 2020 | January 2026 | Allow | 60 | 4 | 0 | Yes | No |
| 16842679 | AAV CAPSID DESIGNS | April 2020 | January 2025 | Abandon | 57 | 5 | 0 | No | No |
| 16651779 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF HEART FAILURE | March 2020 | September 2024 | Allow | 54 | 2 | 1 | Yes | No |
| 16623052 | Demethylation of Reticuline and Derivatives Thereof with Fungal Cytochrome P450 | December 2019 | May 2023 | Allow | 41 | 1 | 1 | Yes | No |
| 16685565 | PURIFICATION AND IDENTIFICATION OF A PROTEIN COMPLEX CONTAINING B-CELL LYMPHOMA PROTEIN (BCL10) | November 2019 | November 2023 | Allow | 48 | 2 | 1 | Yes | No |
| 16494645 | ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF A FRAGMENT OF MICRO-DYSTROPHIN TO TREAT MUSCULAR DYSTROPHY | September 2019 | January 2022 | Allow | 28 | 1 | 0 | Yes | No |
| 16492878 | RIBOSWITCH MODULATED GENE THERAPY FOR RETINAL DISEASES | September 2019 | January 2024 | Allow | 52 | 1 | 1 | Yes | No |
| 16563573 | UNIVERSAL DONOR CELLS | September 2019 | March 2025 | Allow | 60 | 2 | 1 | Yes | No |
| 16512482 | Expression Constructs and Methods for Expressing Polypeptides in Eukaryotic Cells | July 2019 | December 2024 | Abandon | 60 | 1 | 1 | No | No |
| 16457528 | COMPOSITIONS AND METHODS FOR GENOMIC EDITING BY INSERTION OF DONOR POLYNUCLEOTIDES | June 2019 | July 2023 | Allow | 49 | 2 | 1 | Yes | No |
| 16453260 | METHOD TO BUILD FUNGAL PRODUCTION STRAINS USING AUTOMATED STEPS FOR GENETIC MANIPULATION AND STRAIN PURIFICATION | June 2019 | October 2022 | Abandon | 40 | 4 | 1 | Yes | Yes |
| 16472793 | ADENO ASSOCIATED VIRAL VECTORS | June 2019 | March 2025 | Allow | 60 | 1 | 1 | No | No |
| 16341504 | AAV CAPSID DESIGNS | April 2019 | September 2022 | Allow | 42 | 2 | 1 | Yes | No |
| 16279688 | ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR RESTORING F8 GENE FUNCTION AND METHODS OF USE THEREOF | February 2019 | December 2021 | Allow | 34 | 1 | 1 | Yes | No |
| 16270198 | CONSTRUCTS AND METHODS FOR SIGNAL AMPLIFICATION | February 2019 | August 2021 | Abandon | 31 | 2 | 0 | No | No |
| 16322518 | Method for Producing Recombinant Protein | February 2019 | February 2025 | Abandon | 60 | 6 | 0 | Yes | No |
| 16320280 | BCL11A HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE | January 2019 | June 2022 | Abandon | 40 | 1 | 0 | No | No |
| 16252934 | NOVEL SACCHAROMYCES CEREVISIAE EXPRESSION SYSTEM AND CONSTRUCTION METHOD THEREOF | January 2019 | February 2022 | Abandon | 37 | 2 | 1 | No | No |
| 16251970 | Gene Editing-based Method of Attenuating the Beta-Amyloid Pathway | January 2019 | July 2021 | Allow | 29 | 2 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HASAN, KHALEDA B.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HASAN, KHALEDA B works in Art Unit 1636 and has examined 94 patent applications in our dataset. With an allowance rate of 54.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 48 months.
Examiner HASAN, KHALEDA B's allowance rate of 54.3% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HASAN, KHALEDA B receive 2.26 office actions before reaching final disposition. This places the examiner in the 63% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by HASAN, KHALEDA B is 48 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +57.2% benefit to allowance rate for applications examined by HASAN, KHALEDA B. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 16.0% of applications are subsequently allowed. This success rate is in the 12% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 51.4% of cases where such amendments are filed. This entry rate is in the 77% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
When applicants file petitions regarding this examiner's actions, 61.1% are granted (fully or in part). This grant rate is in the 65% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 7.8% of allowed cases (in the 86% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.